Factors Associated with Variceal bleeding in patients with advanced hepatocellular carcinoma treated with Sorafenib or Regorafenib
5 affiliations
- 1Tropical Medicine Department. Faculty of Medicine. Ain Shams university
- 2Department of Internal Medicine, Faculty of Medicine, Ain-Shams university, Cairo, Egypt
- 3Tropical Medicine Department. Faculty of Medicine, Ain Shams University
- 4Internal Medicine Department, Faculty of Medicine, Ain Shams University
- 5Tropical Medicine Department, Faculty of Medicine, Ain Shams University
Abstract
Background: Patients with advanced hepatocellular carcinoma (HCC) under treatment with tyrosine kinase inhibitors (TKI) are at greater risk for gastrointestinal variceal bleeding. This risk in part due to cirrhosis and portal hypertension and in part due to effect of TKI on vascular endothelial growth factor pathway. Aim: to study baseline factors associated with variceal bleeding risk in HCC patients subjected to treatment by TKI. Methods: Patients with advanced HCC treated with TKI in Faculty of Medicine Ain Shams Research Institute (MASRI) during period from May 2024 to May 2025 were evaluated in this observational cohort study performed in Ain Shams University. Baseline characteristics and laboratory investigation were collected, and all patients underwent endoscopic assessment before enrollment in the study and were followed for 6 months. Variceal bleeding episodes were recorded. Results: among 186 patients evaluated, 170 patients were included (46 included prospectively and 124 retrospectively). Patients were followed for 6 months after date of inclusion of last patient. Mean age of participants was 62.7 ± 7.7 years and 75.9% were males. 13 patients developed variceal bleeding attacks during follow up period, all of them had high risk variceal features in baseline endoscopy. Malignant portal vein thrombosis appears to correlate with risk of bleeding and patients who were able to tolerate nonselective beta blockers (NSBB) (carvedilol) appear to have lower variceal bleeding risk. Conclusions: although results showed beneficial effect for carvedilol, prospective larger studies are needed to confirm if nonselective beta blockers had protective effect in this group of patients.
Related
- Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial
- Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
- Acute colonic variceal bleeding treated with coil-assisted retrograde transvenous obliteration following atezolizumab-bevacizumab therapy for advanced hepatocellular carcinoma: A case report.
- USP54 regulates RIPK1 protein abundance via deubiquitination in acquired sorafenib resistance in hepatocellular carcinoma
- Naringenin Enhances the Inhibitory Effect of Regorafenib on HepG2 Hepatocellular Carcinoma Cell Viability with Modulation of E-Cadherin and MRP1 Gene Expression
BibTeX
@article{salaheldin2026factors,
title = {{Factors Associated with Variceal bleeding in patients with advanced hepatocellular carcinoma treated with Sorafenib or Regorafenib}},
author = {Mohamed Salaheldin and Mohamed Fouad and Heba Aly and Marwa Mohamed and Mostafa Shamakh and Dina Fathy},
journal = {Ain Shams Medical Journal},
year = {2026},
month = nov,
doi = {10.21608/asmj.2026.522689.1701},
url = {https://doi.org/10.21608/asmj.2026.522689.1701},
note = {CC BY},
}
RIS
TY - JOUR
TI - Factors Associated with Variceal bleeding in patients with advanced hepatocellular carcinoma treated with Sorafenib or Regorafenib
AU - Mohamed Salaheldin
AU - Mohamed Fouad
AU - Heba Aly
AU - Marwa Mohamed
AU - Mostafa Shamakh
AU - Dina Fathy
PY - 2026
DA - 2026/11/15
JO - Ain Shams Medical Journal
DO - 10.21608/asmj.2026.522689.1701
UR - https://doi.org/10.21608/asmj.2026.522689.1701
AB - Background: Patients with advanced hepatocellular carcinoma (HCC) under treatment with tyrosine kinase inhibitors (TKI) are at greater risk for gastrointestinal variceal bleeding. This risk in part due to cirrhosis and portal hypertension and in part due to effect of TKI on vascular endothelial growth factor pathway. Aim: to study baseline factors associated with variceal bleeding risk in HCC patients subjected to treatment by TKI. Methods: Patients with advanced HCC treated with TKI in Faculty of Medicine Ain Shams Research Institute (MASRI) during period from May 2024 to May 2025 were evaluated in this observational cohort study performed in Ain Shams University. Baseline characteristics and laboratory investigation were collected, and all patients underwent endoscopic assessment before enrollment in the study and were followed for 6 months. Variceal bleeding episodes were recorded. Results: among 186 patients evaluated, 170 patients were included (46 included prospectively and 124 retrospectively). Patients were followed for 6 months after date of inclusion of last patient. Mean age of participants was 62.7 ± 7.7 years and 75.9% were males. 13 patients developed variceal bleeding attacks during follow up period, all of them had high risk variceal features in baseline endoscopy. Malignant portal vein thrombosis appears to correlate with risk of bleeding and patients who were able to tolerate nonselective beta blockers (NSBB) (carvedilol) appear to have lower variceal bleeding risk. Conclusions: although results showed beneficial effect for carvedilol, prospective larger studies are needed to confirm if nonselective beta blockers had protective effect in this group of patients.
SN - 2735-3540
SN - 0002-2144
ER -